Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
PCN Reports : Psychiatry and Clinical Neurosciences|April 4, 2025
Exploratory study of dual-task digital device in children and adolescents with attention-deficit/hyperactivity disorderKatsunaka Mikami, Tasuku Miyajima, Ryo Nishino, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 25, 2020
Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular CarcinomaNaim Alkhouri, Michio Imawari, Namiki Izumi, et al.Modern Rheumatology|November 1, 2016
An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgiaMasato Murakami, Kenichi Osada, Hisao Ichibayashi, et al.Journal of Pain Research|May 2, 2018
A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritisYuji Uchio, Hiroyuki Enomoto, Levent Alev, et al.Neuropsychiatric Disease and Treatment|December 18, 2020
The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical SymptomsNorio Sugawara, Norio Yasui-Furukori, Toshinaga Tsuji, et al.JHEP Reports : Innovation in Hepatology|March 1, 2021
Assessing the periprocedural magnitude of platelet count change in response to lusutrombopagRobert S Brown, Michio Imawari, Namiki Izumi, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 2, 2020
Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open-label studyKazushi Numata, Katsuaki Tanaka, Takayuki Katsube, et al.Advances in Therapy|July 29, 2022
Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing SurveillanceSteven L Flamm, Markus Peck-Radosavljevic, Takahiro Fukuhara, et al.Journal of Gastroenterology|August 15, 2018
A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablationRyosuke Tateishi, Masataka Seike, Masatoshi Kudo, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 4, 2018
Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive ProceduresHisashi Hidaka, Masayuki Kurosaki, Hironori Tanaka, et al.Pageof 3